We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia into Clinical Practice
News

Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia into Clinical Practice

Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia into Clinical Practice
News

Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia into Clinical Practice

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia into Clinical Practice"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Xenomics, Inc. has announced that its first diagnostic test developed for stratification of patients with Acute Myeloid Leukemia (AML) has been implemented at CLIA approved BRT Laboratories Inc. in Baltimore, Maryland, and is available for clinicians.

AML is the most common form of acute leukemia with about 13,400 new cases expected in 2007 in the USA and a similar number in Europe. Early detection of AML subtypes is important for development of a treatment strategy.

The test is based on a recent discovery of Drs. Falini and Mecucci at the Institute of Hematology at the University of Perugia in Italy that mutations in a nucleophosmin (NPM1) gene are characteristic of 30-40% of the cases of AML.

NPM1 is a protein involved in regulation of ribosome biogenesis, cell division, cell death, and other important processes. Xenomics has obtained an exclusive license for the invention and developed a test that detects all 45 known mutations of NPM1 in a single reaction.

The results will help physicians with prognosis, therapy, and monitoring of the disease. Stratification of AML patients is also necessary for anti-AML drug clinical trials.

"We are glad to work with Xenomics on AML diagnostics and to add this test to our repertoire of genetic tests" commented Antonette Allen, Clinical Service Manager of BRT Laboratories. "We believe that the NPM1 diagnostic test will not only help hematologists in the treatment of the disease but also in developing a test for monitoring the disease and patient response to anti-tumor therapy".

Advertisement